Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of divarasib + pembrolizumab versus pembrolizumab + pemetrexed + platinum in untreated KRAS G12C-mutant advanced non-squamous non-small cell lung cancer
CTR20254061Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of divarasib, pembrolizumab, pemetrexed, carboplatin, cisplatin in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Dec 2025; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254061.